Literature DB >> 9575897

A role for PKC epsilon and MAP kinase in bradykinin-induced arachidonic acid release in rabbit CCD cells.

M A Lal1, P R Proulx, R L Hébert.   

Abstract

Arachidonic acid (AA) release is the rate-limiting step in the production of prostaglandins, an important class of autocrine/paracrine factors that modulate collecting duct function. Previous results from this laboratory have established cytosolic phospholipase A2 (cPLA2) as the enzyme responsible for bradykinin (BK)-stimulated AA mobilization in rabbit cortical collecting duct (RCCD) cells, and the present study pursues the intracellular signaling mechanisms responsible for its activation. Pretreatment of cells with Ro-31-8220, an inhibitor of protein kinase C (PKC), or PD-98059, an inhibitor of the mitogen-activated protein kinase (MAPK) cascade, resulted in a 50-60% reduction in BK-stimulated AA release. Incubation of RCCD cells with a combination of both Ro-31-8220 and PD-98059 did not achieve a greater inhibition of either BK-stimulated AA release or cPLA2 activity, possibly indicating that MAPK activation was dependent upon prior activation of PKC. This was supported by the observation that BK-induced MAPK activation could be reversed by either inhibitor. Additional experiments dealing with immunoblots for PKC isozymes revealed that RCCD cells express PKC species alpha, gamma, epsilon, and zeta. Following BK stimulation, only PKC epsilon translocated to the particulate fraction. Based on these results, it appears that PKC is activated and involved in the sequential activation of MAPK and cPLA2 following BK treatment. The results also suggest that PKC epsilon may be the isozyme implicated in the process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9575897     DOI: 10.1152/ajprenal.1998.274.4.F728

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

Review 2.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

3.  In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways.

Authors:  M M Campos; G E Souza; J B Calixto
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+.

Authors:  Mikhail Strokin; Marina Sergeeva; Georg Reiser
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Identification of functional bradykinin B(2) receptors endogenously expressed in HEK293 cells.

Authors:  Inga I Kramarenko; Marlene A Bunni; Thomas A Morinelli; John R Raymond; Maria N Garnovskaya
Journal:  Biochem Pharmacol       Date:  2008-10-01       Impact factor: 5.858

Review 6.  Human tissue kallikrein in the treatment of acute ischemic stroke.

Authors:  Michelle Alexander-Curtis; Rick Pauls; Julie Chao; John J Volpi; Philip M Bath; Todd A Verdoorn
Journal:  Ther Adv Neurol Disord       Date:  2019-01-20       Impact factor: 6.570

7.  The bradykinin B(2) receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines.

Authors:  Inga I Kramarenko; Thomas A Morinelli; Marlene A Bunni; John R Raymond; Maria N Garnovskaya
Journal:  Cancer Manag Res       Date:  2012-07-26       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.